Checkpoint Therapeutics, Inc. (CKPT) financial statements (2020 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26131314223028
Cash and cash equivalents26131314223028
Other current assets0010200
Other undisclosed current assets1111111
Total current assets:27141515253129
Noncurrent Assets
TOTAL ASSETS:27141515253129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:77771286
Accounts payable344410  
Accrued liabilities00000  
Employee-related liabilities00000  
Other undisclosed accounts payable and accrued liabilities3332286
Due to related parties1111111
Other liabilities3      
Other undisclosed current liabilities(3)      
Total current liabilities:88881397
Noncurrent Liabilities
Total liabilities:88881397
Stockholders' equity
Stockholders' equity attributable to parent, including:19677122222
Common stock0000000
Common stock, value, subscriptions3   2  
Additional paid in capital13611811310810510697
Accumulated deficit(120)(111)(106)(101)(95)(84)(74)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:19677122222
TOTAL LIABILITIES AND EQUITY:27141515253129

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0010300
Operating expenses(9)(6)(6)(6)(15)(9)(7)
Operating loss:(9)(5)(5)(6)(12)(9)(7)
Nonoperating income0000000
Investment income, nonoperating0000 00
Net loss available to common stockholders, diluted:(9)(5)(5)(6)(12)(9)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(9)(5)(5)(6)(12)(9)(7)
Comprehensive loss, net of tax, attributable to parent:(9)(5)(5)(6)(12)(9)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: